Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Inclusion Criteria: * Age \> 18 years * Patients must have diagnosis of breast cancer or non small cell lung cancer * Patients must have evaluable disease * Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study. * Patients must have given signed, informed consent prior to registration on study. Exclusion Criteria: * Patients must not be pregnant and/or lactating. * Patients must not be receiving any other investigational agents. * No prior exposure to vinorelbine or other VEGF inhibitors as treatment for metastatic disease * Patients must not have received prior therapy (including radiation, surgery, and/or chemotherapy) within 30 days * History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or vinorelbine. * Patients cannot have received more than 2 prior chemotherapy regimens for lung cancer or 3 prior chemotherapy regimens for breast cancer. This criterion can be discussed further with the study doctor. * Must not have uncontrolled illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmic, psychiatric illness/social situations that would limit compliance with study requirements.